Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study

被引：0
|
作者：
Grob, J. J. [1 ]
Gonzalez Mendoza, R. [2 ]
Basset-Seguin, N. [3 ]
Vornicova, O. [4 ]
Schachter, J. [5 ]
Joshi, A. [6 ]
Meyer, N. [7 ]
Grange, F. [8 ]
Piulats, J. M. [9 ]
Bauman, J. [10 ]
Zhang, P. [11 ]
Gumuscu, B. [11 ]
Swaby, R. F. [11 ]
Hughes, B. G. M. [12 ]
机构：
[1] AIX Marseille Univ, Dermatol, Marseille, France
[2] Ctr Estatal Cancerol Chihuahua, Surg Oncol, Chihuahua, Mexico
[3] Hop St Louis, Dermatol, Paris, France
[4] Rambam Hlth Care Campus, Oncol, Haifa, Israel
[5] Sheba Med Ctr Tel Hashomer, Div Oncol, Ramat Gan, Israel
[6] Townsville Canc Ctr, Med Oncol, Townsville, Qld, Australia
[7] IUCT Oncopole, Med Oncol, Toulouse, France
[8] Hop Robert Debre, CHU Reims, Dermatol Oncol, Reims, France
[9] Hosp Duran & Reinals ICO Hospitalet, Genitourinary Melanoma & Sarcoma Unit, Med Oncol, Barcelona, Spain
[10] Fox Chase Canc Ctr, Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[11] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[12] Univ Queensland, Royal Brisbane & Womens Hosp, Oncol, Brisbane, Qld, Australia
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA72
引用
收藏
页码：908 / 908
页数：1
相关论文
共 50 条
  • [41] Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
    Matulonis, U. A.
    Shapira-Frommer, R.
    Santin, A. D.
    Lisyanskaya, A. S.
    Pignata, S.
    Vergote, I
    Raspagliesi, F.
    Sonke, G. S.
    Birrer, M.
    Provencher, D. M.
    Sehouli, J.
    Colombo, N.
    Gonzalez-Martin, A.
    Oaknin, A.
    Ottevanger, P. B.
    Rudaitis, V
    Katchar, K.
    Wu, H.
    Keefe, S.
    Ruman, J.
    Ledermann, J. A.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1080 - 1087
  • [42] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
    Shi, Y-K.
    Gao, L.
    Tian, Y.
    Chen, J.
    Wang, J.
    Bai, C.
    Li, X.
    Su, H.
    Liu, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
  • [43] Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
    Tang, Patricia A.
    Siu, Lillian L.
    Chen, Eric X.
    Hotte, Sebastien J.
    Chia, Stephen
    Schwarz, James K.
    Pond, Gregory R.
    Johnson, Caitlin
    Colevas, A. Dimitrios
    Synold, Timothy W.
    Vasist, Lakshmi S.
    Winquist, Eric
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (03) : 257 - 264
  • [44] Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results
    Rischin, D.
    Hughes, B. G. M.
    Basset-Seguin, N.
    Schadendorf, D.
    Bowyer, S.
    Trabelsi, S.
    Meier, F.
    Eigentler, T.
    Echarren, V. Casado
    Migden, M. R.
    Hauschild, A.
    Schmults, C. D.
    Yoo, S-Y.
    Paccaly, A.
    Jankovic, V.
    Seebach, F.
    Drutman, S.
    Booth, J.
    Fury, M. G.
    Guminski, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S886 - S887
  • [45] A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
    de Souza, Jonas A.
    Davis, Darren W.
    Zhang, Yujian
    Khattri, Arun
    Seiwert, Tanguy Y.
    Aktolga, Serdal
    Wong, Stuart J.
    Kozloff, Mark F.
    Nattam, Sreenivasa
    Lingen, Mark W.
    Kunnavakkam, Rangesh
    Stenson, Kerstin M.
    Blair, Elizabeth A.
    Bozeman, Jeffrey
    Dancey, Janet E.
    Vokes, Everett E.
    Cohen, Ezra E. W.
    CLINICAL CANCER RESEARCH, 2012, 18 (08) : 2336 - 2343
  • [46] Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
    Patricia A. Tang
    Lillian L. Siu
    Eric X. Chen
    Sebastien J. Hotte
    Stephen Chia
    James K. Schwarz
    Gregory R. Pond
    Caitlin Johnson
    A. Dimitrios Colevas
    Timothy W. Synold
    Lakshmi S. Vasist
    Eric Winquist
    Investigational New Drugs, 2008, 26 : 257 - 264
  • [47] Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma
    Soulieres, Denis
    Cohen, Ezra
    Le Tourneau, Christophe
    Dinis, Jose
    Licitra, Lisa
    Ahn, Myung-Ju
    Soria, Ainara
    Machiels, Jean-Pascal
    Mach, Nicolas
    Mehra, Ranee
    Burtness, Barbara
    Zhang, Pingye
    Cheng, Jonathan
    Swaby, Ramona
    Harrington, Kevin J.
    CANCER RESEARCH, 2018, 78 (13)
  • [48] Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation
    Yamamoto, Kazumasa
    Yamamoto, Shun
    Kato, Ken
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (06) : 667 - 675
  • [49] Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma: An updated analysis.
    Yushak, Melinda Lynne
    Lawson, David H.
    Goings, Monica
    Mckellar, Marjorie
    Maynard, Necia
    Woodruff, Kristin Sieja
    Gorgoglione, Caroline
    McBrien, Stephanie
    Delman, Keith A.
    Lowe, Michael C.
    Kudchadkar, Ragini Reiney
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
    Chow, Laura Q. M.
    Haddad, Robert
    Gupta, Shilpa
    Mahipal, Amit
    Mehra, Ranee
    Tahara, Makoto
    Berger, Raanan
    Eder, Joseph Paul
    Burtness, Barbara
    Lee, Se-Hoon
    Keam, Bhumsuk
    Kang, Hyunseok
    Muro, Kei
    Weiss, Jared
    Geva, Ravit
    Lin, Chia-Chi
    Chung, Hyun Cheol
    Meister, Amy
    Dolled-Filhart, Marisa
    Pathiraja, Kumudu
    Cheng, Jonathan D.
    Seiwert, Tanguy Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) : 3838 - +
12345